Accredited official statistics

Vaccination coverage statistics for children aged up to 5 years, England (COVER programme) report: April 2024 to March 2025

Published 28 August 2025

Applies to England

Health Protection Report, Volume 19 Number 8

First published: 28 August 2025

This report of the cover of vaccination evaluated rapidly (COVER) programme presents annual coverage data for children in the UK who reached their first, second, or fifth birthday during the evaluation year April 2024 to March 2025.

Please note that system changes in 14 upper-tier local authorities (UTLAs) in London earlier this year, as well as changes to the way multiple dose courses are calculated, mean that the coverage in London for some vaccines – particularly the pre-school (dTaP/IPV) booster and MMR2 – is likely to be underestimated. Reported falls in coverage in these vaccines in the current year should not be used in isolation for local vaccination performance management or to direct public health action. Please see Data sources and methodology for more information.

Main points

The main messages of this report are:

• when compared with the previous financial year, coverage in the UK in children aged 12 months increased by 0.1 percentage points for the 6-in-1 vaccine; decreased by 0.1 percentage points for the pneumococcal conjugate vaccine (PCV); increased by 0.3 percentage points for the rotavirus vaccine and increased by 0.3 percentage points for the meningococcal group B (MenB) vaccine
• UK coverage for the pre-school booster (diphtheria, tetanus, pertussis and polio: dTaP/IPV) decreased by 1.2 percentage points, and the second dose of measles, mumps, and rubella (MMR2) decreased by 0.1 percentage points, reflecting vaccinations that should have been delivered between August 2022 to July 2023
• in both Scotland and Wales, coverage for both the 6-in-1 vaccine and first dose of MMR (MMR1) in children aged 5 years exceeded the 95% World Health Organization (WHO) target; in Northern Ireland, in children aged 5 years, coverage for the 6-in-1 was 94.6% and for MMR1 was 93.8%
• in England, coverage in children aged 12 months increased by 0.2 percentage points for the 6-in-1 vaccine; decreased by 0.1 percentage points for the PCV vaccine; increased by 0.3 percentage points for the rotavirus vaccine and increased by 0.4 percentage points for the MenB vaccine
• in England, coverage of MMR1 in children aged 24 months (in children who first became eligible between April 2023 and March 2024) remained stable
• in England, coverage of MMR2 in children aged 5 years decreased by 0.2 percentage points, and coverage of the pre-school booster (dTaP/IPV) decreased by 1.3 percentage points, largely reflecting vaccinations delivered in August 2022 to July 2023
• in England, vaccination coverage varies geographically and is lowest for all antigens in London

The full coverage data by country, region and upper-tier local authority is contained in the separate data file accompanying this report.

The UK Health Security Agency (UKHSA) has taken over the production and publication of the annual Childhood Vaccination Coverage (COVER) Statistics from NHS England, of which this is the first publication. The UKHSA dashboard will be updated with this data at 4pm on 28 August 2025. Please submit any feedback on the presentation or structure of the dashboard via the feedback form, and comments on this publication to COVER@ukhsa.gov.uk.

Coverage in UK countries

Coverage in children aged 12 months

Compared with the previous year, for antigens in children aged 12 months, UK coverage increased by 0.1 percentage points to 91.7% for the 6-in-1, increased by 0.3 percentage points to 89.2% for rotavirus, 0.3 percentage points to 93.4% for PCV, and increased by 0.3 percentage points to 91.3% for MenB.

In Scotland and Wales, coverage in children aged 12 months was above 93% for all antigens except for rotavirus, which was 92.0% in Wales and 92.2% in Scotland. In Northern Ireland coverage was at or above 91% for all antigens except for rotavirus, which was at 88.0%.

Coverage in children aged 24 months

UK coverage remained stable at 92.9% for the 6-in-1, decreased by 0.1 percentage points to 89.3% for MMR1, decreased by 0.1 percentage points to 88.6% for the PCV booster, remained stable at 89.1% for the Hib/MenC booster, and increased by 0.1 percentage points to 87.9% for the MenB booster.

In Scotland and Wales, coverage in children aged 24 months was above 92% for all antigens. In Northern Ireland, coverage was above 87% for all antigens.

Coverage in children aged 5 years

UK coverage increased by 0.1 percentage points to 93.2% for the 6-in-1, decreased by 1.2 percentage points to 82.4% for the dTaP/IPV booster, remained stable at 92.3% for MMR1, decreased by 0.1 percentage points to 84.4% for MMR2, and decreased by 0.5 percentage points to 89.6% for the Hib/MenC booster.

In Scotland, Wales, and Northern Ireland, coverage in children aged 5 years was above 93% for all antigens except for the dTaP/IPV booster and MMR2. These were above 89% coverage in Scotland and Wales, and above 86% coverage in Northern Ireland.

Table 1. Coverage of routine childhood immunisations in the UK, 2024 to 2025

Age at measurement	Vaccine	England (%)	Wales (%)	Scotland (%)	Northern Ireland (%)	United Kingdom (%)
12 months	DTaP/IPV/Hib/HepB	91.4	94.1	94.5	91.0	91.7
12 months	PCV1	93.1	95.7	95.4	93.7	93.4
12 months	Rota	88.8	92.0	92.2	88.0	89.2
12 months	MenB	91.0	93.8	94.0	91.0	91.3
24 months	DTaP/IPV/Hib/HepB Prim	92.5	95.3	95.8	93.1	92.9
24 months	MMR1	88.9	93.0	92.8	89.4	89.3
24 months	Hib/MenC Booster	88.6	92.5	92.9	89.2	89.1
24 months	PCV Booster	88.1	92.7	92.7	89.4	88.6
24 months	MenB Booster	87.4	92.3	92.4	88.1	87.9
5 years	DTaP/IPV/Hib/HepB Prim	92.8	95.4	96.9	94.6	93.2
5 years	MMR1	91.9	95.2	95.3	93.8	92.3
5 years	dTaP/IPV Booster	81.4	89.3	89.7	86.3	82.4
5 years	Hib/MenC Booster	88.9	93.4	94.6	93.1	89.6
5 years	MMR2	83.7	89.5	89.2	86.4	84.4

6-in-1 vaccine (England)

Coverage in children aged 12 months

In England, 12-month coverage of the 6-in-1 increased by 0.2 percentage points to 91.4%.

Across England but excluding London (as this was the region with the lowest coverage), 6-in-1 coverage at 12 months was 92.4%, which is 1.0 percentage points higher than the overall England coverage.

In England over the last 10 years, coverage for the 6-in-1 vaccine peaked at 93.6% in 2015 to 2016. At 91.4%, this year was 2.2 percentage points lower than the peak (Figure 1).

Figure 1. Coverage of the primary course of the 6-in-1 vaccine in England in children aged 12 months from financial year ending 2016 to financial year ending 2025 [note 1]

Note 1: the 5-in-1 (DTaP/IPV/Hib3) vaccine was used prior to August 2017 when it was replaced with the 6-in-1 vaccine (DTaP/IPV/Hib3/HepB). As a result, from quarter 4 of 2018 to 2019, coverage of the 6-in-1 vaccine is reported, rather than 5-in-1.

Compared with the previous year, 6-in-1 coverage decreased in the East of England (0.3 percentage points), and Yorkshire and the Humber (0.1 percentage points).

There was an increase in 6-in-1 coverage in the East Midlands (0.2 percentage points), London (0.1 percentage points), the North East (0.2 percentage points), the North West (0.2 percentage points), the South East (0.1 percentage point), the West Midlands (0.1 percentage points), and the South West (0.4 percentage points).

Figure 2. Coverage of the primary course of the 6-in-1 vaccine by regions in children aged 12 months from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the 6-in-1 vaccine for 2024 to 2025 by UTLA in children aged 12 months is presented in Figure 3.

Figure 3. Coverage of the 6-in-1 vaccine in children aged 12 months in England for 2024 to 2025 by UTLA

6-in-1 vaccine: coverage in children aged 24 months

In England, 24-month coverage of the 6-in-1 increased by 0.1 percentage points to 92.5%.

In England over the last 10 years, coverage for the 6-in-1 vaccine peaked at 95.2% in 2015 to 2016. At 92.5%, this year was 2.7 percentage points lower than the peak (Figure 4).

Figure 4. Coverage of the primary course of the 6-in-1 vaccine in England in children aged 24 months from financial year ending 2016 to financial year ending 2025 [note 1]

Note 1: the 5-in-1 (DTaP/IPV/Hib3) vaccine was used prior to August 2017 when it was replaced with the 6-in-1 vaccine (DTaP/IPV/Hib3/HepB). As a result, from quarter 4 of 2018 to 2019, coverage of the 6-in-1 vaccine is reported rather than 5-in-1.

Across England but excluding London (as this was the region with the lowest coverage), 6-in-1 coverage at 24 months was 93.6%, which is 1.1 percentage points higher than the overall England coverage.

Compared with the previous year, 6-in-1 coverage decreased in London (0.6 percentage points) and the West Midlands (0.1 percentage points).

There was an increase in 6-in-1 coverage in the East Midlands (0.5 percentage points), the East of England (0.1 percentage points), the North West (0.1 percentage points), Yorkshire and the Humber (0.1 percentage points), the South East (0.4 percentage points), and the South West (0.2 percentage points).

6-in-1 coverage remained stable in the North East.

Figure 5. Coverage of the 6-in-1 vaccine by regions in children aged 24 months from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the 6-in-1 vaccine for 2024 to 2025 by UTLA in children aged 24 months is presented in Figure 6.

Figure 6. Coverage of the 6-in-1 vaccine in children aged 24 months in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the 6-in-1 vaccine in children aged 24 months varies by UTLA. The data underlying Figure 6 is available in the accompanying data file.

Coverage in children aged 5 years

In England, 5-year coverage of the 6-in-1 increased by 0.2 percentage points to 92.8%.

In England over the last 10 years, coverage for the 6-in-1 vaccine peaked at 95.6% in 2016 to 2017. At 92.8%, this year was 2.8 percentage points lower than the peak (Figure 7).

Figure 7. Coverage of the primary course of the 6-in-1 vaccine in England in children aged 5 years from financial year ending 2016 to financial year ending 2025 [note 1]

Note 1: the 5-in-1 (DTaP/IPV/Hib3) vaccine was used prior to August 2017 when it was replaced with the 6-in-1 vaccine (DTaP/IPV/Hib3/HepB). As a result, from quarter 4 of 2018 to 2019, coverage of the 6-in-1 vaccine is reported rather than 5-in-1.

Across England excluding London (as this was the region with the lowest coverage), 6-in-1 coverage for children aged 5 years was 94.1%, which is 1.3 percentage points higher than the overall England coverage.

Children aged 5 years in this year were born from April 2019 to March 2020. When they were aged 12 months, coverage for the 6-in-1 was 92.0%. By 24 months it was 93.0%. This year, when aged 5 years, it is 92.8%. As compared with birth cohorts from the previous 5 years, coverage for the 6-in-1 has followed a similar pattern of increasing from 12 to 24 months, and then stabilizing by 5 years. However, the increase from 12 to 24 months has been less than previous birth cohorts.

Birth cohorts over time do not necessarily include the same children due to population movement. This birth cohort included 610,509 children at 12 months, increasing to 619,634 at 24 months, and then increasing further to 653,173 at 5 years.

Figure 8. Coverage of the 6-in-1 vaccine across England in children aged 5 years when they were aged 12 months, 24 months, and 5 years

Compared with the previous year, 6-in-1 coverage decreased in the East of England (0.1 percentage points), London (0.4 percentage points), the North West (0.1 percentage point), and in Yorkshire and the Humber (0.4 percentage points).

There was an increase in 6-in-1 coverage in the East Midlands (1.3 percentage points), the South East (0.7 percentage points), the North East (0.3 percentage points), and the South West (0.4 percentage points. In the West Midlands, 6-in-1 coverage remained stable.

Figure 9. Coverage of the 6-in-1 vaccine by regions in children aged 5 years from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the 6-in-1 vaccine for 2024 to 2025 by UTLA in children aged 5 years is presented in Figure 10.

Figure 10. Coverage of the 6-in-1 vaccine in children aged 5 years in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the 6-in-1 vaccine in children aged 5 years varies by UTLA. The data underlying Figure 10 is available in the accompanying data file.

dTaP/IPV booster (England)

Coverage in children aged 5 years

In England, 5-year coverage of the dTaP/IPV booster decreased by 1.3 percentage points to 81.4%.

In England over the last 10 years, coverage for the dTaP/IPV booster peaked at 86.3% in 2015 to 2016. At 81.4%, this year was 4.9 percentage points lower than the peak (Figure 11).

Figure 11. Coverage of the dTaP/IPV booster in England in children aged 5 years from financial year ending 2016 to financial year ending 2025

Across England but excluding London (as this was the region with the lowest coverage), dTaP/IPV booster coverage at 5 years was 85.0%, which is 3.6 percentage points higher than the overall England coverage.

Compared with the previous year, dTaP/IPV booster coverage decreased in the East Midlands (0.6 percentage points), the East of England (0.4 percentage points), London (9.0 percentage points), and Yorkshire and the Humber (0.4 percentage points).

There was an increase in dTaP/IPV booster coverage in the North West (0.8 percentage points), the North East (0.1 percentage points), the South East (0.9 percentage points), and the South West (0.5 percentage points). In the West Midlands, dTaP/IPV booster coverage remained stable.

Figure 12. Coverage of the dTaP/IPV booster by regions in children aged 5 years from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the dTaP/IPV booster for 2024 to 2025 by UTLA in children aged 5 years is presented in Figure 13.

Figure 13. Coverage of the dTaP/IPV booster in children aged 5 years in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the dTaP/IPV booster in children aged 5 years varies by UTLA. The data underlying Figure 13 is available in the accompanying data file.

MMR1 vaccine (England)

Coverage in children aged 24 months

In England, 24-month coverage of the MMR1 vaccine remained stable at 88.9%.

In England over the last 10 years, coverage for the MMR1 vaccine peaked at 91.9% in 2015 to 2016. At 88.9%, this year was 3.0 percentage points lower than the peak (Figure 14).

Figure 14. Coverage of the MMR1 vaccine in England in children aged 24 months from financial year ending 2016 to financial year ending 2025

Across England excluding London, as the region with the lowest coverage, MMR1 vaccine coverage at 24 months was 90.6%, which is 1.7 percentage points higher than the overall England coverage.

Compared with the previous year, MMR1 vaccine coverage decreased in the East of England (0.2 percentage points), London (1.0 percentage point), and Yorkshire and the Humber (0.2 percentage points).

There was an increase in MMR1 vaccine coverage in the East Midlands (0.1 percentage points), the North West (0.3 percentage points), the South East (0.3 percentage points), and the West Midlands (0.4 percentage points).

MMR1 coverage remained stable in the North East and the South West.

Figure 15. Coverage of the MMR1 vaccine by regions in children aged 24 months from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the MMR1 vaccine for 2024 to 2025 by UTLA in children aged 24 months is presented in Figure 16.

Figure 16. Coverage of the MMR1 vaccine in children aged 24 months in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the MMR1 vaccine in children aged 24 months varies by UTLA. The data underlying Figure 16 is available in the accompanying data file.

Coverage in children aged 5 years

In England, 5-year coverage of the MMR1 remained stable at 91.9%.

In England over the last 10 years, coverage for the MMR1 vaccine peaked at 95.0% in 2016 to 2017. At 91.9%, this year was 3.1 percentage points lower than the peak (Figure 17).

Figure 17. Coverage of the MMR1 vaccine in England in children aged 5 years from financial year ending 2016 to financial year ending 2025

Across England but excluding London (as this was the region with the lowest coverage), MMR1 coverage at 5 years was 93.4%, which is 1.5 percentage points higher than the overall England coverage.

Compared with the previous year, MMR1 coverage decreased in the East Midlands (0.1 percentage points), London (0.8 percentage points), the North West (0.1 percentage points), and Yorkshire and the Humber (0.4 percentage points).

There was an increase in MMR1 coverage in the South East (0.3 percentage points), the North East (0.3 percentage points), and the South West (0.4 percentage points).

In the following regions, MMR1 coverage remained stable: the East of England and the West Midlands.

Figure 18. Coverage of the MMR1 vaccine by regions in children aged 5 years from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the MMR1 vaccine for 2024 to 2025 by UTLA in children aged 5 years is presented in Figure 19.

Figure 19. Coverage of the MMR1 vaccine in children aged 5 years in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the MMR1 vaccine in children aged 5 years varies by UTLA. The data underlying Figure 19 is available in the accompanying data file.

MMR2 vaccine (England)

Coverage in children aged 5 years

In England, 5-year coverage of the MMR2 vaccine decreased by 0.2 percentage points to 83.7%.

In England over the last 10 years, coverage for the MMR2 vaccine peaked at 88.2% in 2015 to 2016. At 83.7%, this year was 4.5 percentage points lower than the peak (Figure 20).

Figure 20. Coverage of the MMR2 vaccine in England in children aged 5 years from financial year ending 2016 to financial year ending 2025

Across England excluding London (as this was the region with the lowest coverage), MMR2 vaccine coverage for children aged 5 years was 86.7%, which is 3.0 percentage points higher than the overall England coverage.

Compared with the previous year, MMR2 vaccine coverage decreased in the East Midlands (0.2 percentage points), London (3.7 percentage points), and Yorkshire and the Humber (0.1 percentage point).

There was an increase in MMR2 vaccine coverage in the North West (1.1 percentage points), North East (0.5 percentage points), the South East (1.0 percentage points), the South West (0.6 percentage points), and the West Midlands (0.5 percentage points).

In the East of England, MMR2 coverage remained stable.

Figure 21. Coverage of the MMR2 vaccine by regions in children aged 5 years from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the MMR2 vaccine for 2024 to 2025 by UTLA in children aged 5 years is presented in Figure 22.

Figure 22. Coverage of the MMR2 vaccine in children aged 5 years in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the MMR2 vaccine in children aged 5 years varies by UTLA. The data underlying Figure 22 is available in the accompanying data file.

Rotavirus (England)

Coverage in children aged 12 months

In England, 12-month coverage of the rotavirus vaccine increased by 0.3 percentage points to 88.8%.

In England over the last 10 years, coverage for the rotavirus vaccine peaked at 90.2% in 2020 to 2021. At 88.8%, this year was 1.4 percentage points lower than the peak (Figure 23).

Figure 23. Coverage of the rotavirus vaccine in England in children aged 12 months from financial year ending 2016 to financial year ending 2025

Across England excluding London (as this was the region with the lowest coverage), rotavirus vaccine coverage at 12 months was 89.9%, which is 1.1 percentage points higher than the overall England coverage.

Compared with the previous year, there was an increase in rotavirus vaccine coverage in the East of England (0.1 percentage points), London (0.3 percentage points), the North East (0.3 percentage points), the North West (0.6 percentage points), the South East (0.4 percentage points), the South West (0.3 percentage points), the West Midlands (0.5 percentage points), and Yorkshire and the Humber (0.1 percentage points).

In the East Midlands, rotavirus coverage remained stable.

Figure 24. Coverage of the rotavirus vaccine by regions in children aged 12 months from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the rotavirus vaccine for 2024 to 2025 by UTLA in children aged 12 months is presented in Figure 25.

Figure 25. Coverage of the rotavirus vaccine in children aged 12 months in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the rotavirus vaccine in children aged 12 months varies by UTLA. The data underlying Figure 25 is available in the accompanying data file.

PCV (England)

Coverage in children aged 12 months

In England, 12-month coverage of PCV decreased by 0.1 percentage points to 93.1%.

In England over the last 10 years, coverage for PCV peaked at 93.8% in 2021 to 2022. At 93.1%, this year was 0.7 percentage points lower than the peak (Figure 26).

Figure 26. Coverage of PCV in England in children aged 12 months from financial year ending 2016 to financial year ending 2025 [note 2]

Note 2: from quarter 4 (January to March) 2020 to 2021, PCV1 rather than PCV2 is reported to reflect the change in the PCV schedule.

Across England excluding London, as the region with the lowest coverage, PCV coverage at 12 months was 94.2%, which is 1.1 percentage points higher than the overall England coverage.

Compared with the previous year, PCV coverage decreased in the East of England (0.3 percentage points), London (0.8 percentage points), the North East (0.2 percentage points), and Yorkshire and the Humber (0.3 percentage points).

There was an increase in PCV coverage in the North West (0.2 percentage points), and the West Midlands (0.3 percentage points).

In the East Midlands, the South West, and the South East, PCV coverage remained stable.

Figure 27. Coverage of the PCV vaccine by regions in children aged 12 months from financial year ending 2016 to financial year ending 2025 [note 2]

Note 2: from quarter 4 (January to March) 2020 to 2021, PCV1 rather than PCV2 is reported to reflect the change in the PCV schedule.

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for PCV for 2024 to 2025 by UTLA in children aged 12 months is presented in Figure 28.

Figure 28. Coverage of PCV in children aged 12 months in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of PCV in children aged 12 months varies by UTLA. The data underlying Figure 28 is available in the accompanying data file.

Coverage in children aged 24 months

In England, 24-month coverage of the PCV booster decreased by 0.1 percentage points to 88.1%.

In England over the last 10 years, coverage for the PCV booster peaked at 91.5% in 2016 to 2017. At 88.1%, this year was 3.4 percentage points lower than the peak (Figure 29).

Figure 29. Coverage of the PCV booster in England in children aged 24 months from financial year ending 2016 to financial year ending 2025

Across England excluding London (as this was the region with the lowest coverage), PCV booster coverage at 24 months was 89.9%, which is 1.8 percentage points higher than the overall England coverage.

Compared with the previous year, PCV booster coverage decreased in the East of England (0.3 percentage points), London (1.2 percentage points), and Yorkshire and the Humber (0.7 percentage points).

There was an increase in PCV booster coverage in the East Midlands (0.1 percentage points), the North East (0.2 percentage points), the North West (0.2 percentage points), the South East (0.5 percentage points), and the West Midlands (0.4 percentage points).

PCV booster coverage remained stable in the South West.

Figure 30. Coverage of the PCV booster by regions in children aged 24 months from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for PCV booster for 2024 to 2025 by UTLA in children aged 24 months is presented in Figure 31.

Figure 31. Coverage of the PCV booster in children aged 24 months in England for 2024 to 2025 by UTLA

Hib/MenC booster (England)

Due to the cessation of routine Hib/MenC (Menitorix) offer to children aged 1 year, this is the last annual report on this booster. Please refer to the letter on the childhood schedule changes for more information.

Coverage in children aged 24 months

In England, 24-month coverage of the Hib/MenC booster remained stable at 88.6%.

In England over the last 10 years, coverage for the Hib/MenC booster peaked at 91.6% in 2015 to 2016. At 88.6%, this year was 3.0 percentage points lower than the peak (Figure 32).

Figure 32. Coverage of the Hib/MenC booster in England in children aged 24 months from financial year ending 2016 to financial year ending 2025

Across England excluding London (as this was the region with the lowest coverage), Hib/MenC booster coverage at 24 months was 90.4%, which is 1.8 percentage points higher than the overall England coverage.

Compared with the previous year, Hib/MenC booster coverage decreased in London (1.0 percentage points) and Yorkshire and the Humber (0.5 percentage points).

There was an increase in Hib/MenC booster coverage in the East Midlands (0.1 percentage points), the North East (0.2 percentage points), the North West (0.3 percentage points), the South East (0.3 percentage points), and the West Midlands (0.4 percentage points).

Hib/MenC booster coverage remained stable in the East of England and the South West.

Figure 33. Coverage of the Hib/MenC booster by regions in children aged 24 months from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the Hib/MenC booster for 2024 to 2025 by UTLA in children aged 24 months is presented in Figure 34.

Figure 34. Coverage of the Hib/MenC booster in children aged 24 months in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the Hib/MenC booster in children aged 24 months varies by UTLA. The data underlying Figure 34 is available in the accompanying data file.

Coverage in children aged 5 years

In England, 5-year coverage of the Hib/MenC booster decreased by 0.5 percentage points to 88.9%.

In England over the last 10 years, coverage for the Hib/MenC booster peaked at 92.6% in 2015 to 2016. At 88.9%, this year was 3.7 percentage points lower than the peak (Figure 35).

Figure 35. Coverage of the Hib/MenC booster in England in children aged 5 years from financial year ending 2016 to financial year ending 2025

Across England excluding London, as the region with the lowest coverage, Hib/MenC coverage for children aged 5 years was 90.8%, which is 1.9 percentage points higher than the overall England coverage.

Compared with the previous year, Hib/MenC coverage decreased in the East Midlands (1.1 percentage points), the East of England (0.3 percentage points), London (2.5 percentage points), the North East (0.5 percentage points), the North West (0.1 percentage points), and Yorkshire and the Humber (1.0 percentage point).

There was an increase in Hib/MenC coverage in the South East (0.4 percentage points), the South West (0.7 percentage points), and the West Midlands (0.1 percentage points).

Figure 36. Coverage of the Hib/MenC booster by regions in children aged 5 years from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the Hib/MenC booster for 2024 to 2025 by UTLA in children aged 5 years is presented in Figure 37.

Figure 37. Coverage of the Hib/MenC booster in children aged 5 years in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the Hib/MenC booster in children aged 5 years varies by UTLA. The data underlying Figure 37 is available in the accompanying data file.

MenB (England)

Coverage in children aged 12 months

In England, 12-month coverage of the MenB vaccine increased by 0.4 percentage points to 91.0%.

In England over the last 10 years, coverage for the MenB vaccine peaked at 92.5% in 2017 to 2018. At 91.0%, this year was 1.5 percentage points lower than the peak (Figure 38).

Figure 38. Coverage of the MenB vaccine in England in children aged 12 months from financial year ending 2018 to financial year ending 2025

Across England excluding London, as the region with the lowest coverage, MenB coverage at 12 months was 92.2%, which is 1.2 percentage points higher than the overall England coverage.

Compared with the previous year, MenB coverage decreased in the East of England (0.1 percentage points).

There was an increase in MenB coverage in the East Midlands (0.5 percentage points), the North East (0.5 percentage points), the North West (0.4 percentage points), the South East (0.2 percentage points), the South West (0.7 percentage points), the West Midlands (0.9 percentage points), and Yorkshire and the Humber (0.2 percentage points).

In London, MenB coverage remained stable.

Figure 39. Coverage of the MenB vaccine by regions in children aged 12 months from financial year ending 2018 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the MenB vaccine for 2024 to 2025 by UTLA in children aged 12 months is presented in Figure 40.

Figure 40. Coverage of the MenB vaccine in children aged 12 months in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the MenB vaccine in children aged 12 months varies by UTLA. The data underlying Figure 40 is available in the accompanying data file.

MenB booster (England)

Coverage in children aged 24 months

In England, 24-month coverage of the MenB booster booster increased by 0.1 percentage points to 87.4%.

In England over the last 10 years, coverage for the MenB booster peaked at 89.0% in 2020 to 2021. At 87.4%, this year was 1.6 percentage points lower than the peak (Figure 41).

Figure 41. Coverage of the MenB booster in England in children aged 24 months from financial year ending 2019 to financial year ending 2025

Across England excluding London (as this was the region with the lowest coverage), MenB booster coverage at 24 months was 89.2%, which is 1.8 percentage points higher than the overall England coverage.

Compared with the previous year, MenB booster coverage decreased in the East of England (0.3 percentage points), London (0.8 percentage points), and Yorkshire and the Humber (0.3 percentage points.

There was an increase in MenB booster coverage in the East Midlands (0.3 percentage points), the North East (0.2 percentage points), the North West (0.5 percentage points), the South East (0.7 percentage points), the South West (0.1 percentage points), and the West Midlands (0.6 percentage points).

Figure 42. Coverage of the MenB booster by regions in children aged 24 months from financial year ending 2016 to financial year ending 2025

Coverage varies by geography. Full coverage data by country, region and UTLA is contained in the separate data file accompanying this report. Coverage for the MenB vaccine for 2024 to 2025 by UTLA in children aged 24 months is presented in Figure 43.

Figure 43. Coverage of the MenB booster in children aged 24 months in England for 2024 to 2025 by UTLA

Source of vaccine coverage data: UK Health Security Agency

Source of boundaries: Office for National Statistics licensed under the Open Government Licence v.3.0. Contains OS data © Crown copyright and database right 2025

Coverage of the MenB vaccine in children aged 24 months varies by UTLA. The data underlying Figure 43 is available in the accompanying data file.

Selective neonatal vaccination programmes in England

Hepatitis B (HepB)

In England, coverage at 12 months for 5 doses of a HepB-containing vaccine was 93.4%. Coverage of 6 doses of a HepB-containing vaccine reported for children who reached 2 years of age in the reporting year was 89.3% (see the separate data file accompanying this report).

The quality of neonatal HepB vaccine data is variable and coverage by former local teams can be based on small numbers. As such, comparisons of percentages should be considered alongside denominators. Where an area reported no vaccinated children, a check was made to ensure that this was zero reporting rather than absence of available data.

Bacillus Calmette-Guérin (BCG)

The data captures BCG coverage at 3 months for children born January 2024 to December 2024 and at 12 months for children born April 2023 to March 2024. It was provided for all local authorities in England and is published in the data tables associated with this report. In children aged 3 months, coverage in England was 78.2% and in children aged 12 months, it was 84.7%.

Coverage in unregistered children in London

Due to uncertainty in the numbers of children not registered with GPs in 14 UTLAs in London, these figures for London are reported separately. For antigens measured in these children aged 12 months, coverage was 20.8% for the 6-in-1, 20.4% for MenB, 26.9% for PCV, and 25.2% for rotavirus. For antigens measured in these children aged 24 months, coverage was 29.2% for the 6-in-1, 11.4% for MMR1, 11.1% the for Hib/MenC booster, 10.6% for the PCV booster, and 10.4% for the MenB booster. For antigens measured in these children aged 5 years, coverage was 39.8% for the 6-in-1, 3.4% for the dTaP/IPV booster, 25.6% for the Hib/MenC booster, 27.5% for MMR1, and 6.8% for MMR2.

These results should be considered in light of the uncertainty in the numbers of children not registered with GPs and are likely to underestimate true coverage in this group.

Data sources and methodology

Data was received from all health boards in Wales, Scotland and Northern Ireland. In England, local teams and Child Health Record Departments provided data for all UTLAs and the associated general practices.

In this report and the accompanying data set: Hackney is included in the City of London, Rutland is included in Leicestershire, the Isles of Scilly are included in Cornwall, and Cumbria is reported as a single UTLA.

System changes earlier this year in 14 UTLAs in London, as well as changes to the way multiple doses are calculated, have affected reported coverage in London for some vaccines, particularly the pre-school booster (dTaP/IPV) and MMR2. Coverage for these vaccines is likely underestimated and reported falls in coverage in these vaccines in the current year should not be used in isolation to performance manage vaccination services at the local level or direct public health action until further investigation is undertaken. Work is underway to fully understand these apparent decreases in reported coverage and ensure reporting is consistent and comparable between regions.

Additionally, until data on children not registered with a GP can be validated, for these UTLAs only children registered with a GP are included in the London-, England-, and UK-level figures. The affected UTLAs are Greenwich, Hammersmith and Fulham, Kensington and Chelsea, Lambeth, Lewisham, Southwark, Westminster, Bexley, Brent, Bromley, Ealing, Harrow, Hillingdon, and Hounslow. Reported coverage in these UTLAs will be higher than coverage measured when including the unregistered population. However, these coverage estimates will more closely reflect the true coverage in the population until the data on children not registered with a GP is fully validated.

These statistics are subject to both scheduled revisions and unscheduled corrections and are therefore marked as provisional. In addition to correction of any errors made during the production of these statistics, unscheduled corrections also include the correction of errors later identified within the source data received by UKHSA. Revisions and corrections are made timely and transparently in line with UKHSA’s published Revisions and corrections policy.

Further information on the data quality and methodology of these statistics are published in the Quality and methodology information report.

Background information

This publication is released on an annual basis and aligns with the financial year from April to March the following calendar year.

Children who reached their first birthday in this year would have been scheduled to receive their primary course (third dose) of the combined diphtheria, tetanus, acellular pertussis vaccine, inactivated poliomyelitis vaccine, haemophilus influenzae type b vaccine and hepatitis B vaccine (DTaP/IPV/Hib/HepB3 or 6-in-1 vaccination) which protects against diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenzae type b (Hib) and hepatitis B, and their primary course (second dose) of MenB vaccine which protects against meningococcal group B disease at the age of 16 weeks, August 2023 to July 2024. They would have also been scheduled to receive a single dose of PCV (protecting against pneumococcal disease) and 2 doses of rotavirus vaccine at age 12 weeks, July 2023 to June 2024.

Except for the rotavirus vaccine which is only offered up to 6 months of age, all other vaccines are available to children in the current cohort at any time and would have been captured in this report if given by their first birthday. Children born to hepatitis B surface antigen (HBsAg) positive mothers who reached their first birthday in this year should also have received monovalent hepatitis B vaccine at birth and at 4 weeks of age.

Children who reached their second birthday would have been scheduled to receive their primary course (third dose) of the 6-in-1 vaccination August 2022 to July 2023 and their first MMR vaccination, a Hib/MenC booster (protecting against haemophilus influenzae type b and meningococcal group C disease), MenB booster and PCV booster at one year of age April 2023 to March 2024. Children born to HBsAg positive mothers, who reached their second birthday in this year (born April 2022 to March 2023), were scheduled to receive a third dose monovalent hepatitis B vaccine at one year of age.

Children who reached their fifth birthday would have been scheduled to receive their primary course (third dose) of the 6-in-1 vaccination August 2019 to July 2020, their first MMR and the Hib/MenC booster April 2020 to March 2021, their pre-school diphtheria, tetanus, acellular pertussis and polio (DTaP/IPV) booster, and second-dose MMR from August 2022 to July 2023.

Children born in areas where tuberculosis (TB) incidence is greater than or equal to 40 per 100,000 or who are born to parents or grandparents from TB endemic areas were eligible for a BCG vaccination at 28 days. Coverage is in children aged 3 months of age and 12 months of age for this selective immunisation.

The full routine immunisation schedule sets out the schedule for all childhood immunisations.

Related statistics

• Interactive dashboard
• Quarterly data for England
• Annual data for England
• Data for Wales
• Data for Scotland
• Data for Northern Ireland

Further information and contact details

The submission and publication dates for this report series are available as is additional information for immunisation practitioners and other health professionals.

Future publications of this report series may include aggregation of the GP data to the primary care network (PCN) level, and links to code for analysis at regional and local levels.

Feedback and contact information

For any questions or comments regarding this report, please email cover@ukhsa.gov.uk.

Official statistics

Our statistical practice is regulated by the Office for Statistics Regulation (OSR). OSR sets the standards of trustworthiness, quality and value in the Code of Practice for Statistics that all producers of official statistics should adhere to. You can contact OSR by emailing regulation@statistics.gov.uk or via the OSR website.

UKHSA is committed to ensuring that these statistics comply with the Code of Practice for Statistics. This means users can have confidence in the people who produce UKHSA statistics because our statistics are robust, reliable and accurate. Our statistics are regularly reviewed to ensure they support the needs of society for information.

UKHSA has conducted a formal review of these statistics. Following this review, an implementation plan has been developed to continue to improve the trustworthiness, quality, and value of these statistics. Key continuous improvements made will be highlighted within future releases of these statistics for transparency.